On November 30, 2021 Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, reported the successful completion of its OB-004 lead optimization (Press release, Orion Biotechnology, NOV 30, 2021, View Source [SID1234596387]). OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor. The CCL2/CCR2 pathway plays an important role in oncology, inflammatory, metabolic, and neurological disorders.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Using its proprietary drug discovery technology, Orion successfully completed the development of OB-004 from target identification to lead optimization in only 6 months, a significant reduction in discovery time compared to industry averages. Furthermore, based on inhibition of in vitro signaling, OB-004 is a best-in-class CCR2 antagonist compared to other small molecule CCR2 antagonists in development. This is yet another example demonstrating the superiority of Orion’s discovery platform and novel drug modality to target complex GPCRs.
"Development of a best-in-class CCR2 antagonist in 6 months is an extraordinary accomplishment and validates the power and versatility of our drug discovery platform" said Dr. Oliver Hartley, Vice President of Drug Discovery at Orion Biotechnology. "This powerful tool will allow Orion to rapidly expand its pipeline and also provides us with the opportunity to collaborate with other groups in facilitating the identification and development of GPCR targeted drugs, including the ability to target orphan GPCRs".
Dr. Ian McGowan, Chief Medical Officer at Orion Biotechnology, added "The rapid development of a potent CCR2 antagonist will provide us with the opportunity to evaluate OB-004 in several important diseases with significant unmet medical need including oncological, metabolic, and inflammatory disorders. I look forward to advancing OB-004 into preclinical efficacy studies early next year".